Lai’s previous research focused on nanoparticle-based delivery of bioactive molecules to mucosal tissues. He helped pioneer the development of mucus-penetrating particle technology, a breakthrough that formed the basis of Kala Pharmaceuticals, launched in 2009 based on funding from a syndicate of leading VC firms. Since moving to UNC, he has established a rigorous research program at the interface of engineering, immunology, biophysics and biomaterials. His lab recently spun out Mucommune, LLC, a startup focused on harnessing antibody-mucin interactions to prevent or treat infectious diseases at mucosal surfaces.
Lai’s current research interests include mucosal immunology and mucosal barriers to infectious disease, antibody response to synthetic materials, targeted nanoparticle delivery using bispecific fusion proteins and computational modeling of physiological processes. For more info, please see his lab website.
Note that the Lai Research Group is actively recruiting highly motivated members at all levels (postdoc, graduate students, undergraduates) from across all disciplines.
Education, Entrepreneurship and Outreach
To promote entrepreneurship and innovation among graduate students, professional students and postdocs, Lai has created the E(I) Lab program, an 8-month long experiential education program that bring together students from diverse disciplines across UNC to conceive, develop and test innovative solutions to unmet needs in healthcare.
Lai has also collaborated with the Morehead Planetarium and Science Center to develop laboratory module and education curriculum for middle school students titled What’s Snot to Like [PDF]. The curriculum is part of the Morehead Mobile Labs program.